18th BIOSIMILAR MEDICINES CONFERENCE

October 6-7, 2022 | USA

18th BIOSIMILAR
During this in-person event, speakers and panellists will explore how to turn the Pharmaceutical Strategy aim to ensure better access and affordability into concrete biosimilar medicine policy measures.

Spotlight

Lung cancer rates are dropping, but it remains second-most-common cancer in both men and women (excluding skin cancer). About 14 percent of all new cancers are lung cancers, and most of those are NSCLC. But today, the outlook for patients is improving, in large part because immunotherapy is transforming the way cancers are treated.


OTHER PAST CONFERENCES

24th World Congress On Pharmaceutical Research and Drug Discovery

November 21-22, 2022 | Singapore

The pharma is the art and science of preparing, compounding and dispensing medications. It also includes the more modern services related to the health care and the provision of drug and related information to the public.

20th International Conference on Pharmaceutical Medicine

October 19-21, 2022 | Greece

2022 is a special year. We will be celebrating the long-awaited return of the 20th ICPM since the last one in 2018. It will also be the first time that ICPM will be accessible both on-site and on-line, ensuring you can access the very latest science and research updates, from wherever you are.

GLOBAL CONFERENCE ON PHARMACEUTICALS AND CLINICAL RESEARCH

November 14-16, 2022 | France

On behalf of Scientex Conferences we cordially invite you to attend “Global Conference on Pharmaceuticals and Clinical Research” on November 14-16, 2022 at Paris, France. It mainly focuses on the theme “Futuristic Advancements in Pharmaceuticals and Clinical Research”.

East West BioPharma Summit

November 14-16, 2022 | USA

BioCentury and BayHelix invite you to Register Now to join us at the East-West BioPharma Summit at the Grand Bay Hotel San Francisco, Redwood City, CA on Nov. 14-16, 2022.

Spotlight

Lung cancer rates are dropping, but it remains second-most-common cancer in both men and women (excluding skin cancer). About 14 percent of all new cancers are lung cancers, and most of those are NSCLC. But today, the outlook for patients is improving, in large part because immunotherapy is transforming the way cancers are treated.

resources